A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE).

Trial Profile

A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2016

At a glance

  • Drugs PD 360324 (Primary)
  • Indications Cutaneous lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Jan 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 01 Dec 2013 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
    • 01 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top